Innate Pharma

IPHANasdaq France Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$156.369 M

$1.40 +0.71%

Close of 6 Nov 2026

As of 6 Nov 2026, Innate Pharma (IPHA) has a market capitalization of $156.4M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

93,719,323

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#98CompugenCGEN$183.0M
#99InvivydIVVD$171.6M
#100Innate PharmaIPHA$156.4M
#101Sutro BiopharmaSTRO$152.0M
#102Protara TherapeuticsTARA$125.9M

What if Innate Pharma were worth as much as…

Open the what-if tool →

Gold $28.2T

$252,791.28

Per share 180,578× higher

Bitcoin $1.53T

$13,678.10

Per share 9,771× higher

Apple $5.02T

$44,903.91

Per share 32,077× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Innate Pharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.